Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Myeloid 5CNS 4Sarcoma 3Plasma cell 3Other hematologic neoplasm 3Thoracic 2Lymphoid 2Breast 2Gastrointestinal 1Dermatologic 1

Conditions

Neoplasms, Plasma Cell 3Multiple Myeloma 3Recurrence 2

Interventions

Dexamethasone 882Bortezomib 481Lenalidomide 467Cyclophosphamide 367Melphalan 276Calcium Dobesilate 265daratumumab 241pomalidomide 216carfilzomib 188fludarabine phosphate 141fludarabine 137Thalidomide 125Peripheral Blood Stem Cell Transplantation 120Filgrastim 115ixazomib 94Mycophenolic Acid 91Granulocyte Colony-Stimulating Factor 90Busulfan 89Whole-Body Irradiation 88dexamethasone acetate 87Tacrolimus 79dexamethasone 21-phosphate 74isatuximab 70Cyclosporine 68auricularum 67Prednisone 67elotuzumab 63belantamab mafodotin 60Antilymphocyte Serum 56Etoposide 53

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
imetelstat × Plasma cell × Clear all
NCT01242930 2016-05-12

Open Label Study With Imetelstat to Determine Effect of Imetelstat in Patients w/ Previously Treated Multiple Myeloma

Geron Corporation

Phase 2 Completed
13 enrolled
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00594126 2015-12-24

Safety and Dose Study of GRN163L Administered to Treat Patients With Refractory or Relapsed Multiple Myeloma

Geron Corporation

Phase 1 Completed
20 enrolled
Plasma cell

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT00718601 2015-12-24

Safety and Dose Study of GRN163L and Velcade to Treat Patients With Refractory or Relapsed Myeloma

Geron Corporation

Phase 1 Completed
40 enrolled
Plasma cell

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡